# OnCo record nct06093841 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06093841/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06093841", "NCT06093841" ;
  schema:name "Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL"@en ;
  schema:description "A phase 2 trial of Relmacabtagene autoleucel, Fludarabine, Cyclophosphamide in follicular lymphoma, run by Shanghai Ming Ju Biotechnology Co., Ltd., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06093841/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06093841> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-11-03" ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:drugs <https://onco.cc/drugs/relmacabtagene-autoleucel/>, <https://onco.cc/drugs/fludarabine/>, <https://onco.cc/drugs/cyclophosphamide/> ;
  onco:companies <https://onco.cc/companies/jw-therapeutics/> .